000			01566nam a2200133Ia 4500
008			220615s9999||||xx |||||||||||||| ||und||
020			_a9783040000000
245		0	_aDrug Absorption Studies: In Situ, In Vitro and In Silico Models
546			_aEnglish[eng]
650			_arebamipide||nanocrystals||oral mucositis||hydrogel||endocytosis||enoxaparin||lipid–polymer hybrid nanoparticles||oral||intestinal absorption||naftidrofuryl oxalate||solubility||permeability||dissolution profiles||pharmaceutical availability||BCS drug classification||non-sink condition||solubility–permeability interplay||unstirred water layer||poorly soluble drugs||solubilizer additive||phenylketonuria||l-phenylalanine ammonia-lyase||enzyme||kinetics||catabolism disorder||biomedical drug||P-glycoprotein||breast cancer resistance protein||LY335979||WK-X-34||in vivo–in vitro correlation||lipolysis-permeation||lipid-based drug delivery system||PermeaPad||cinnarizine||lipolysis||amorphous solid dispersion||candesartan Cilexetil||PVPK30||pH-modulation||spray drying||bioavailability||nasal administration||spray-drying||chitosan||microsphere||meloxicam||silymarin||D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS)||liver distribution||acetaminophen-induced hepatotoxicity||extra virgin olive oil||secoiridoids||metabolism||phenolic compounds||intestinal permeability||drug-phytochemical interaction||hepatic metabolism||mixed inhibition||quercetin||repaglinide
700			_aSong, Im-Sook
856			_uhttps://mdpi.com/books/pdfview/book/4689
942			_cEB
999			_c18644 _d18644